Search clinical trials for: CNTO 3649

Total 230 results

University Medical Center Groningen
Janssen-Cilag Ltd.

Completed

Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (HiGUS)

Hidradenitis Suppurativa

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis (U-POPS)

Psoriasis | Arthritis, Juvenile | Juvenile Psoriatic Arthritis

United States
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Crohn Disease

United States, Korea, Republic of, Netherlands, France, Austria, Italy, United Kingdom, Germany, Russian Federation, Spain, Czechia, Sweden
Janssen-Cilag S.p.A.

Completed

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis (GULLIVER)

Psoriasis

Italy
Janssen Pharmaceutical K.K.

Completed

A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice

Ulcerative Colitis

Japan
Janssen Research & Development, LLC

Terminated

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Japan, Korea, Republic of, Canada, Taiwan, Thailand, Germany, China, Serbia, Spain, Portugal, Russian Federation, Poland, Ukraine, Lithuania, South Africa, Hungary, Argentina, Bulgaria, Colombia
Janssen Research & Development, LLC

Completed

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (VEGA)

Colitis, Ulcerative

United States, Russian Federation, Australia, Poland, Germany, Brazil, Ukraine, Argentina, Mexico
Janssen Cilag S.A.S.

Completed

Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases (TENOR)

Crohn Disease | Colitis, Ulcerative

France
Janssen Research & Development, LLC

Completed

A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection (PROGRESS)

Crohn's Disease

United States, Poland
Emory University
National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH); EUSA Pharma, Inc...

Completed

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Janssen-Cilag Ltd.

Terminated

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis (G-CARE)

Psoriasis

Italy, Germany, Greece
Janssen-Cilag Ltd.

Completed

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab (STARDUST)

Crohn Disease

Belgium, Netherlands, United Kingdom, France, Czechia, Italy, Germany, Denmark, Spain, Portugal, Slovakia, Sweden
Janssen Inc.

Completed

Golimumab for Adherence in Rheumatoid Arthritis (GO FAR)

Arthritis, Rheumatoid

Canada
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Takayasu Arteritis

Japan
Janssen Research & Development, LLC

Suspended

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Germany, United States, United Kingdom, Belgium
Janssen Research & Development, LLC
Children's Hospital Medical Center, Cincinnati; ImproveCareNow (ICN)

Completed

A Study of Ustekinumab Treatment in Children With Crohn's Disease (REALITI)

Crohn's Disease

United States
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, France, Israel, Netherlands, Poland, Puerto Rico, Spain, Sweden
Janssen-Cilag Ltd.

Terminated

A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care Providers

Crohn Disease

United Kingdom
Janssen Scientific Affairs, LLC

Completed

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)

Crohn Disease

United States, Belgium, Korea, Republic of, Netherlands, Italy, United Kingdom, Canada, France, Australia, Bulgaria, Poland, Germany, Serbia, Czechia, Russian Federation, Spain, Brazil, Hungary
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Colitis, Ulcerative

United States, France, Belgium, Israel, Canada, Netherlands, Austria, Poland, Denmark, Germany
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease (STELARA)

Crohn Disease

United States, Belgium, Canada, France, Poland, Germany
Janssen Research & Development, LLC

No longer available

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

Diabetes Mellitus, Type 1

United States
Janssen Korea, Ltd., Korea

Completed

Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab) (STELARA CD PMS)

Crohn Disease

Korea, Republic of
Johnson & Johnson Private Limited

Completed

A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

Arthritis, Psoriatic | Spondylitis, Ankylosing

India
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Australia, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Israel, Bulgaria, Romania, Serbia, Japan, Canada, Netherlands, Korea, Republic of, New Zealand, Russian Federation, Austria, Hungary, Slovakia, D... and more
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Turkey, Malaysia, Czechia, Bulgaria, Poland, Russian Federation, Ukraine, Spain, Taiwan, Latvia, Estonia, Lithuania
Janssen Research & Development, LLC

Completed

A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes (T1GER)

Diabetes Mellitus, Type 1

United States
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Healthy | Arthritis, Psoriatic

Austria
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Critical Confirmed Coronavirus Disease (COVID)-19

United States
Janssen Research & Development, LLC

No longer available

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen-Cilag Ltd.

Completed

Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)

Crohn Disease

Sweden
Janssen-Cilag Ltd.

Completed

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (G-PLUS)

Psoriasis

Germany, France, Italy, Spain, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age (CADMUS Jr)

Psoriasis

United States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
Janssen-Cilag S.p.A.

Completed

A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs (SIRENA)

Spondyloarthritis, Axial and Peripheral

Italy
Janssen Research & Development, LLC

Completed

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

Pre-Symptomatic Type 1 Diabetes

United States, Finland, Sweden
Janssen Research & Development, LLC

Completed

A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

Psoriasis

United States, Australia, Taiwan, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Poland, Hungary
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2)

Psoriasis

United States, Australia, Poland, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Czechia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

Hidradenitis Suppurativa

United States, France, Canada, Germany, Netherlands, Denmark
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) (Discover-1)

Arthritis, Psoriatic

United States, Canada, Taiwan, Hungary, Malaysia, Germany, Czechia, Korea, Republic of, Russian Federation, Spain, Australia, Ukraine, Poland
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Janssen Research & Development, LLC

No longer available

An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

Crohn Disease

Brazil
Janssen Research & Development, LLC

Withdrawn

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more

Search clinical trials for: CNTO 3649

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations